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Abstract 
Background: Myomectomy is a surgical technique used for removal of uterine fibroids and historically hysterectomy 
has represented the mainstay of treatment. The options of conservative surgical approaches mainly aim at reten-
tion of fertility but have to be balanced against potential risks such as haemorrhage; blood loss at myomectomy 
still remains troublesome with use of various pharmacologic agents yielding inconclusive results. This trial aimed to 
explore the benefit of combining ornipressin and tranexamic acid during open myomectomy.
Study design: A randomized double blind placebo controlled trial.
Methods: Women who satisfied eligibility criteria were enrolled into the study and randomized into one of two 
groups. The experimental group received 1 g of tranexamic acid diluted to 50 ml of saline administered at 100 ml 
per hour at cutting time (knife to skin). The control group received placebo diluted to 50 ml of saline administered at 
100 ml per hour at cutting time. Both groups had five international units ornipressin diluted in 60 ml of saline admin-
istered during surgery. The primary outcome (blood loss) was assessed by determining the weight difference of dry 
and soaked swabs using a digital weighing scale by converting this to volume (ml). Operating time was noted from 
the time of uterine incision to the time of uterine closure. The need for transfusion was determined by anaesthetists’ 
assessment of acceptable blood loss and clinical assessment of vital signs. Post-operative stay was calculated from the 
time of extubation to 8 am on the day of discharge.
Results: A total of thirty-four patients were randomized to two groups; 17 received ornipressin only and 17 received 
tranexamic acid and ornipressin. There was no difference in blood loss between the groups with a median blood loss 
in the ornipressin (n = 17) and ornipressin plus tranexamic acid arms of 398 ml (IQR: 251–630) ml and 251 ml (IQR: 
158–501) ml respectively P = 0.361.
Conclusions: Ornipressin administered along with tranexamic acid is not beneficial for blood loss reduction at open 
myomectomy. In settings such as ours where myomata are prevalent and severe anaemia rampant, blood donation 
and judicious use of scarce blood resources is key. Efforts to optimize preoperative haemoglobin levels and blood 
auto-donation seem the most promising options in pre-operative preparation prior to myomectomy.
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Background
Uterine myomata are the most common benign solid 
tumours of the female genital tract and are diagnosed 
in about 25–30  % of women [1]. The overall prevalence 
of fibroids in Black African population is estimated at 
50–75 %, forming the primary diagnosis for 61 % of black 
and 29 % of white women [2]. Several options are avail-
able for the management of symptomatic fibroids. These 
can broadly be grouped into expectant, medical and sur-
gical methods. Surgical methods include uterine fibroid 
embolization, laparoscopic myomectomy, hysteroscopic 
resection, hysterectomy or open myomectomy. Myomec-
tomy carries a significant risk of haemorrhage with a 
transfusion rate of 21  % [3]. Several interventions to 
reduce blood loss have been explored including vasopres-
sin analogues, antifibrinolytic agents, and gonadotropin 
releasing hormone analogues, oxytocin, misoprostol and 
mechanical tourniquets [4]. These studies have drawn 
conclusions from single agents versus placebo but none 
has utilized adjunct techniques against methods con-
sidered standard protocol. At the Aga Khan University 
Hospital the use of ornipressin is considered standard 
practice by most gynaecologists during open myomec-
tomy and has occasionally been utilized with other addi-
tional drugs like tranexamic acid in an attempt to reduce 
intra operative haemorrhage. There are no randomized 
trials comparing adjunctive use of tranexamic acid along 
with ornipressin during open myomectomy and hence 
the need to establish its utility when used along with 
ornipressin.
Methods
Study design
This randomized double blind controlled trial compared 
blood loss between two groups of participants, one receiving 
ornipressin only and the other ornipressin and tranexamic 
acid. Patients were recruited from the gynaecology clinics at 
the Aga Khan University Hospital. Patients with documented 
uterine fibroids on ultrasound scan were recruited following 
discussion and gave written consent to participate.
The sampling frame included all women attending 
gynaecology clinic at the Aga Khan University Hospi-
tal. Patients with symptomatic uterine fibroids-heavy 
menses, pressure symptoms, and painful menses were 
recruited for the study. Study subjects were eligible to be 
enrolled into the study if they had documented symp-
tomatic uterine fibroids by ultrasound imaging, written 
informed consent, no prior treatment using gonadotro-
pin releasing hormone analogues, no family history of 
bleeding disorder, no current use of anticoagulants, and 
no prior history of deep venous thrombosis. They were 
excluded if they had poorly controlled hypertension 
or diabetes and previous uterine fibroid embolization. 
Sample size calculation was set at 90 % power to detect a 
150 ml difference in blood loss, with a significant level of 
5 % and a one sided alpha of 0.05 and beta (β)-set at 0.1.
The sample size was calculated using the formula 
below.
Substituting with figures:
Patients with documented evidence of uterine fibroids 
on ultrasound who had decided on open myomectomy 
were enrolled at the gynaecology outpatient clinic. At 
this point the surgical procedure informed consent was 
signed. Block randomization was achieved by a com-
puter generated sequence operated by the pharmacist. 
The computer generated list of interventions consisted 
of four blocks containing a plain normal saline in 50 ml 
syringe and one gram of tranexamic acid diluted to 
50 ml of normal saline. Random allocation to each block 
was made and patients allocated as per the flow of the 
block sequence as indicated so as to achieve allocation 
concealment.
3.
1. 4. 7.
2. 5. 8.
6. 9.
TTPP
PTTP
TPTP
PTPT
PPTT
PTPT
PTTP
TTPP
TPTP
where T is test (Tranexamic acid) and P is Placebo (Nor-
mal Saline).
This ensured even distribution in both arms of the 
study [5].
The study assistant submitted the patient’s identifica-
tion to the pharmacist which was entered against the 
intervention allocated thus keeping the randomization 
code unknown to the study assistant. Aseptically freshly 
prepared solution (50 ml syringe) of 1 g tranexamic acid 
in 50 ml or 50 ml normal saline (placebo) was issued to 
the study assistant packed in an opaque envelope and 
delivered to the operating room. Tranexamic acid pre-
pared in the pharmacy is a clear solution that was diluted 
to 50 ml in a normal saline solution and therefore indis-
tinguishable to the 50  ml normal saline placebo, thus 
assuring blinding of the surgeon, anaesthetist and data 
collector. The study assistant delivered the dispensed 
solution to theatre. The 50  ml solution loaded onto the 
infusion pump was started at cutting time (knife to 
skin) running at a rate of 100 ml per hour. All study par-
ticipants enrolled received ornipressin (5 international 
N = 2�2(zα+ Z1/2β)2/r2
N = 2× 135× 135(1.96+ 1.282)2
/
1502
= 17 patients in each group.
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units diluted to 60  ml) infiltrated around the myomata. 
Soaked swabs were weighed and blood loss estimated by 
subtracting the soaked weight from the dry weight and 
multiplied by 1.050 to convert to volume in ml [6]. The 
myomata location was documented post operatively by 
the surgeon.
Duration of surgery was calculated in minutes noted 
from the time of incision on the uterus to placement of 
the last uterine stitch, by the theatre circulating nurse. 
Post-operative stay was calculated from the time of extu-
bation to 8  am on the day of discharge in hours after 
satisfying discharge criteria (Appendix). The volume 
of the myoma was determined using the Archimedes 
principle by immersion of all the fibroids in a measur-
ing cylinder with water calibrated in ml. The need for 
transfusion was assessed by the anaesthetist if there 
was significant haemorrhage defined by the vital signs 
BP 90/60  mmHg  or lower, heart rate >110  b/min and 
or a calculated threshold of blood loss necessitating 
transfusion obtained by: Hb threshold of 8  g/dl, there-
fore allowable blood loss was considered equal to total 
Blood volume (Pre-operative Hb  −  Hb threshold/Pre 
op Hb). Blood loss beyond this threshold necessitated 
blood transfusion. Serious adverse outcomes of the 
study included death, massive transfusion >5 units of 
blood, development of deep venous thrombosis pulmo-
nary edema and pulmonary embolism. The study was 
approved by the Aga Khan University Research Ethics 
Committee.
Results
Participant flow for the study is shown in Fig. 1. Data were 
available for 17 participants in each group. Clinical and 
operative findings are presented in Table 1. Operating time 
and estimated blood loss are shown in Table 2. There were 
no major postoperative complications or study medica-
tion related adverse events in either group. Data analysis 
was performed using STATA version 12 special edition 
(STATA/SE). Categorical variables were summarized as 
frequencies (n) and the corresponding percentages (%) 
while the continuous variables that were normally distrib-
uted were summarized as mean and the corresponding 
standard deviation (std). Continuous variables that were 
skewed were transformed using the logarithm to base 10. 
The variables that were transformed were blood loss, oper-
ation time, and myoma volume. The test for differences 
between the categorical variables and the treatment group 
was conducted using the Pearson’s Chi Square test and 
because of the small cell counts for all the variables Fish-
er’s exact was utilized. The relationship between the con-
tinuous variables was assessed using Pearson’s correlation 
coefficient. The test for differences in the continuous vari-
ables between the treatment groups was done using the 
two-sample t test if the normality assumption was holding. 
However, if the normality assumption was violated, then a 
two sample Wilcoxon rank sum test was used. The test for 
differences in the continuous variables between the treat-
ment groups was done using the two-sample t test. Assess-
ment for the validity of a t test was also done.
Fig. 1 Flow of study participants
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There was no variable that appeared to confound the 
true effect of the treatment. There were no missing data 
for all the variables.
A strong statistically significant association between 
myoma volume and blood loss was identified (Fig.  2). 
Stratified by the treatment arm, the same trend was seen 
with correlation coefficient equal to 0.890 in the orni-
pressin and tranexamic acid group and 0.850 in the orni-
pressin group (P < 0.0001).
Discussion
This study found that there is no additional benefit in 
adjunct tranexamic acid use to ornipressin during open 
myomectomy. This is the first study to our knowledge to 
investigate adjunctive use of tranexamic acid along with 
intramyometrial ornipressin during open myomectomy 
to assess for intraoperative blood loss. Open myomec-
tomy remains a surgical option for women of low par-
ity with large myomata desiring fertility. Haemorrhage 
Table 1 Demographic and baseline clinical characteristics in both groups
Variables Group P
Ornipressin only (n = 17) Tranexamic acid and ornipressin (n = 17)
Continuous variables Mean (std) Mean (std)
Age (years) 35.0 (3.9) 36.0 (4.3) 0.536
Pre operation HB 12.8 (1.3) 12.6 (1.9) 0.760
BMI (kg m−2) 29.9 (3.7) 29.6 (2.8) 0.775
Categorical variables n (%) n (%) P
Indication for surgery
 Heavy menses 12 (71 %) 14 (82 %) 0.261
 Pressure symptoms 2 (12 %) 3 (18 %)
 Subfertility 3 (18 %) 0 (0)
Uterine incision
 Anterior vertical 9 (53 %) 8 (47 %) 1.000
 Anterior transverse 2 (12 %) 2 (12 %)
 Bonney’s Hood 1 (6 %) 0 (0 %)
 Posterior transverse 1 (6 %) 2 (12 %)
 Posterior vertical 4 (24 %) 5 (29 %)
Position of myoma
 Intramural 15 (88 %) 13 (76 %) 0.656
 Subserosal 2 (12 %) 4 (24 %)
Table 2 Outcomes in both groups
a The two sample Wilcoxon rank sum test for differences in quantity of blood loss between the ornipressin and the ornipressin plus tranexamic arms showed no 
evidence of statistically significant difference. Data were log transformed
Continuous variables Group P
Ornipressin only (n = 17) Tranexamic acid and ornipressin (n = 17)
Mean (std) Mean (std)
Blood loss a 398 ml (251–630) ml 251 ml (158–501) ml 0.361
Intra operative time (min) t − 0.23; 
df = 32; P = 1.000
50.1 50.1 1.000
Post-operative stay (h) (t − 1.69, 
P = 0.100)
67.88 (22.98) 55.03 (21.22) 0.100
Post operation HB 10.2 (2.1) 10.3 (1.9) 0.939
Surgicel use
 Yes 4 (24) % 4 (24) % 1.000
 No 13 (76) % 13 (76) %
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is a possibility and use of various agents to reduce blood 
loss is vital. There are no studies with similar objec-
tives to compare blood loss reduction when multiple 
agents are used adjunctively. Concerns of utilizing hor-
monal tourniquets and substances that increase uterine 
tone at myomectomy include concealing active bleed-
ers that eventually become active post operatively lead-
ing to post-operative haemorrhage, not to mention other 
untoward effects like fever, chills and rigors with the use 
of misoprostol [7]. The ‘triple tourniquet’ technique has 
been used and showed significant results in blood loss 
reduction at myomectomy [8] compared to gonadotropin 
releasing hormone analogues. According to our findings 
large myomata are more likely to bleed as depicted by 
the correlation co efficient of 0.89 in the ornipressin plus 
tranexamic acid group and 0.85 in the ornipressin group. 
This indicates that the amount of blood loss is depend-
ent on the volume of the myoma removed. It can there-
fore be insinuated that use of techniques that will reduce 
myomata volume pre operatively are likely to reduce 
blood loss at surgery. Gonadotrophin releasing hormone 
analogues have been utilized pre operatively with sub-
stantial reduction in myoma volume and correction of 
anaemia [8] however multiple challenges including cost, 
unfavorable side effects (menopausal symptoms, loss of 
bone mineral density hot flushes etc.) have limited its 
use. Other concerns include fibroid recurrence after ces-
sation of gonadotrophin releasing hormone analogue use 
as well as difficult dissection planes encountered intraop-
eratively [8].
Uterine fibroid embolization offers a plausible alterna-
tive to open surgery for fibroids especially for patients not 
keen on surgery or whose indication for hysterectomy is 
due to uterine fibroids and has become a well established 
modality offered in our unit. A case series in Turkey com-
pared participants who had UFE before myomectomy 
and those who had myomectomy alone; their conclusion 
was that there was significant reduction in intra operative 
blood loss and a 13  % need for transfusion in the latter 
group [9]. It is unclear whether this combined approach 
is really clinically useful given the additional costs of two 
interventions and it is not our standard practice.
One patient was excluded at recruitment who had been 
re admitted due to heavy menses and pressure symptoms 
after having uterine fibroid embolization 2 years before. 
The use of fibroid embolization for patients keen on fer-
tility however remains unclear, open myomectomy still 
offers better   pregnancy outcomes. The Mara trial con-
cluded spontaneous miscarriage rates were higher in 
patients who underwent fibroid embolization, 60 % ver-
sus 23 % in those who had open myomectomy [10]. This 
study population had 8.8 % of participants whose indica-
tion for surgery was subfertility.
Additional efforts pre operatively include optimizing 
haemoglobin levels using oral or parenteral haematinics, 
gonadotropin agonists and encouraging auto donation 
of blood to avoid risks of blood transfusion like allergic 
reactions, infections, transfusion associated lung injury 
and transfusion associated circulatory overload [11].
Uterine fibroids are more prevalent in the black pop-
ulation and possibly larger in volume; multiple large 
fibroids will ultimately require judicious surgical skill 
to minimize blood loss. Surgeons intending to perform 
myomectomies for large myoma especially in settings 
where patients are symptomatic for anaemia need to 
consider optimizing pre-operative haemoglobin and pre-
pare blood before surgery. Transfusion may be inevitable 
when an initial haemoglobin level is already low and its 
complications likely due to multiple transfusions hence 
the importance of optimizing haemoglobin pre opera-
tively. Human and financial resources remain scarce in 
the local setting and health policy makers need to invest 
in strengthening referral systems, optimizing blood 
donation processes and ensuring quality training of ser-
vice providers who will offer patients options for correct 
management of fibroids even if it means conservative 
approaches through to uterine fibroid embolization.
The findings of this study additionally shed light on 
the unexplored combined use of various pharmacologic 
agents at myomectomy. The study was powered to detect 
the difference in blood loss at ninety percent power and 
based on this, a difference in blood loss was not observed 
between both groups. In future, studies of this nature 
should probably attempt to obtain a sample size based 
on how much blood loss would like to be avoided so as 
to recruit those who bleed excessively beyond a preset 
threshold. This will require a large number of participants 
and possibly as a multi-center study to demonstrate the 
true effect of the intervention on patients who are likely 
Fig. 2 Myoma volume and blood loss
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to bleed excessively. The study had proper randomiza-
tion and blinding yielding the true effect of the interven-
tion and both groups were similar at baseline making the 
results generalizable. Most Kenyan rural institutions may 
not have the advantage of having hormonal tourniquets 
due to cost, thus application of similar interventions may 
be hindered.
Strengths
Randomization and blinding was achieved satisfactorily. 
The surgeon, principal investigator and anaesthesiolo-
gist undertaking procedure in theatre were blinded to the 
intervention hence eliminating potential bias in theatre. 
This ensured the true effect of intervention being cap-
tured which is key in studies of this nature. Secondly all 
patients received the intervention at the same time and 
same flow rate by use of an infusion pump, something 
similar studies have failed to standardize.
Limitations
Surgeon’s technique at myomectomy could not be fully 
standardized due to various myoma positions.
Conclusion
Adjunct tranexamic acid use to ornipressin during open 
myomectomy does not have any benefit in reducing 
blood loss. Large myoma volume notably found in the 
black population are likely to bleed and hence there is a 
need for judicious surgical skill and strategies to reduce 
blood loss.
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Appendix: Discharge criteria
  • Patient in good general condition.
  • Normal vital signs (Blood pressure, Heart Rate, Tem-
perature).
  • Second day post operative haemoglobin done and 
recorded in the file.
  • No clinical and laboratory pointers of infection.
  • Patient remains discharged from the study even if she 
is still in the ward but sorting out other non medical 
issues e.g. hospital fees, awaiting drugs.
  •
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